News & Updates

Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.

Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).

The intravesical instillation of onabotulinumtoxinA (onabotA) for refractory overactive bladder in urinary incontinence is generally safe and well-tolerated, but demonstrates no significant efficacy advantage over placebo, according to a recent study.

For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.

Men with prostate cancer have altered gut microbiota composition, according to a study presented at the recent Annual Congress of the European Association of Urology (EAU 2022). This association may partly explain the documented links between lifestyle or geographic location and prostate cancer.

For male patients with inflammatory bowel disease (IBD), treatment with biologic, thiopurine, or methotrexate does not appear to promote impairments in fertility or adverse pregnancy outcomes, according to a study.